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Abstract Refractory chronic migraine (RCM) is often
associated with disability and a low quality of life (QOL).
RCM ranges in severity from mild to severe. There would
be a beneﬁt both clinically and in research use in catego-
rizing RCM patients according to severity. This study
utilized a unique RCM severity rating scale, tracking the
clinical course over 10 years. A total of 129 patients, ages
19–72, were assigned a severity rating of 2–10 (10 =
worst). Pain level and QOL were assessed. Over the
10 years, 73% of all pts. had a 30% or more decline in
pain. Pain levels improved 45% in mild pts., 42% in mod.
pts., and 36% in severe pts. Pain was the same, or worse, in
4% of mild, 15% of mod., and 18% of severe pts. QOL in
the mild group improved 35% over 10 years. In moderate
pts., QOL improved 32%, while for the severe group QOL
improved 33%. While pain and QOL improved across all
three groups at the end of 10 years, the severe group
remained with signiﬁcantly more pain and decreased QOL
than in the milder groups. The medications that helped
signiﬁcantly included: opioids (63% of pts. utilized opi-
oids), frequent triptans (31%), butalbital (17%), onabotul-
inumtoxinA (16%), stimulants (12%), and other ‘‘various
preventives’’ (9%). RCM pts. were rated using a refractory
rating scale with the clinical course assessed over 10 years.
Pain and QOL improved in all groups. In the severe group,
pain and QOL improved, but still lagged behind the mild
and moderate groups. Opioids and (frequent) triptans were
the most commonly utilized meds.
Keywords Chronic migraine  Refractory chronic
migraine  Refractory headache  Chronic daily headache
Introduction
Refractory chronic migraine (RCM) is often a debilitating
illness with an enormous impact on QOL. The Refractory
Headache Special Interest Section (RHSIS) of the Ameri-
can Headache Society (AHS) has provided a forum for
physicians on this crucial topic. Chronic migraine occurs in
approximately 2% of the population [1]; the prevalence of
RCM is unknown.
Much work has been accomplished on the deﬁnition of
RCM [2]. A summary of the current proposed criteria is
listed (see Table 1). The deﬁnition is a continuous work in
progress [3]. Long-term outcomes for those with RCM
have not been investigated. In addition, there is a range of
severity among the RCM patients. For clinical and research
purposes, it is important to categorize the RCM patients
according to severity.
This study assessed pain and quality of life (QOL) in
RCM patients over a 10-year period. A novel RCM
‘‘severity rating scale’’ was used for the evaluation of these
patients.
Methods
Design and patient selection
This was a retrospective chart review of 129 RCM patients.
RCM was diagnosed according to criteria suggested by the
Refractory Headache Special Interest Section of the AHS
(Table 1).
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old as of the year 2000. The patients were followed at our
headache center during the years 2000–2010, and must
have remained at the clinic for that time. A total of 129
pts., with an average age of 49 (108 F, ages 19–72, and
21 M, ages 31–69), were assessed.
Refractory scale
A refractory scale of this author’s design was utilized for
assessment. The scale ranges from 2 (least severe) to 10
(most severe) (see Table 2).
The patients were assigned a number (2–10) as of the
year 2000, and this assignment of severity was not reas-
sessed after the initial date.
The severity groupings were as follows: score of 2, 3, or
4: mild RCM, score of 5, 6, 7: moderate RCM, and score of
8, 9, 10: severe RCM.
Outcome measures and data collection
Quality of life QOL was measured by adding pain, func-
tioning, and mood scores (each on a 1–10 scale, with
1 = best, 10 = worst). The QOL rating scale ranged from
3 (best) to 30 (worst). Pain was assessed via a visual analog
scale of 1–10 (10 = worst). Functioning was determined
by the level of the work and/or home activities. Mood
determinates included depression, anxiety, and insomnia.
These were assessed using DSM-IV criteria.
Pain level Pain was assessed using a visual analog scale,
1–10 (10 = worst).
Data collection This is a retrospective study. Data were
collected by the treating physician. Data were ‘‘de-identi-
ﬁed’’ and collected as anonymous ‘‘batch’’ data. Informed
consent was obtained. A local IRB was consulted.
Statistics
SPSS (Statistical Package for Social Sciences v17 for Win-
dows)wasusedforthestatisticalanalyses.Differencescores
for QOL1-QOL2 and pain ratings time1–time2 were calcu-
lated. To analyze if these pre–post scores differed across the
three pain severity groups (mild, moderate, severe), a one-
way analysis of variance (ANOVA) was conducted. To
determine if treatment was signiﬁcantly effective in
decreasing level of pain and improving QOL, pre–post
pairedsamplettestswerecalculatedforeachseveritygroup.
Finally, Cohen’s effect size formula [(mean1 – mean2)/(the
average ofstandarddeviation1 ? standarddeviation2)]was
used for paired sample t tests.
Results
A total of 129 patients (N = 129 patients; 108 F, ages
19–72, 21 M, ages 31–69, average age 49) were initially
categorized according to the refractory scale (2–10,
10 = most refractory). QOL (Table 3) and pain level
(Table 4) were assessed as of the year 2000, and also 2010.
For the mild patients, 66% improved by 30% or more in
QOL during the 10 years. In the moderate group, 57%
improved by 30% or more, and in the severe group 61%
improved by 30% or more.
Table 1 Refractory chronic migraine criteria (proposed) [3]
1. Patient has diagnosis of chronic migraine (or migraine)
2. Patient has failed adequate trial of at least two out of four drug
classes
a. Anticonvulsants
b. Beta blockers
c. Tricyclics
d. Calcium channel blockers
3. Patient has modiﬁed lifestyle and eliminated triggers
4. Patient has failed abortive medications, including:
a. Triptans and DHE
b. NSAIDs and combination analgesics
5. There may be modiﬁers:
a. With or without medication overuse
b. With signiﬁcant disability
Table 2 Refractory scale (2–10, 10 = most severe)
1. Refractory to preventives = 2 points (refractory to preventives
is determined by RHSIS [3] and Silberstein [4] criteria)
2. Refractory to abortives = 2 points (determined by RHSIS [3]
and Silberstein [4] criteria)
3. Greater than 10 years of chronic migraine = 1 point (chronic
migraine deﬁned according to International Headache Society
(IHS) criteria [5])
4. 25 or more days of headache per month (on average) = 1 point
5. Two of the following associated medical conditions: irritable
bowel syndrome (IBS), ﬁbromyalgia, temporal mandibular
dysfunction (TMD), chronic pelvic pain, painful bladder
syndrome, and chronic fatigue = 1 point. These syndromes were
deﬁned according to guidelines established by the various
specialty organizations. Patients had to have been diagnosed
using the standard criteria [6]
6. Psychiatric comorbidities of the following types: severe Axis I
(affective disorder), or any Axis II (personality disorder) = 1
point. These were diagnosed utilizing guidelines established in
DSM-IV [7]
7. Disability (work and/or home) = 1 point. The pts. had to
demonstrate moderate to severe disability with poor functioning
for at least 6 months. Disability was assessed by the treating
physician and included interviews with the patient and family.
A VAS functioning scale was utilized to aid in disability
assessment
8. Medication overuse headache = 1 point. Criteria established by
the IHS were utilized [5]
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mild pts., 16% moderate, and in 18% of severe pts.
ANOVA revealed signiﬁcant mean change score (time1–
time2) differences for QOL ratings between severity groups
[F(2,126) = 4.31, p = 0.02]. Bonferroni post hoc results
showed that improvements in QOL after treatment were
signiﬁcantlylargerfortheseveregroupcomparedtothemild
group (p = 0.045) and for the severe group relative to the
moderate group (p = 0.03). Change scores for the mild to
moderate group did not signiﬁcantly differ.
In the mild group, 80% of the pts. had a decline in pain
levels of 30% or more over the 10 years. In the moderate
group, 72% had a decline in pain levels of 30% or more.
The severe group had 71% of pts. with a decline in pain of
30% or more over the 10 years.
Pain levels were the same, or worse, over the 10 years in
only 4% of mild pts., 15% of moderate, and in 18% of the
severe pts. ANOVA ﬁndings for the change scores in pain
ratingsfailedtoyieldanybetweenseveritygroupdifferences.
60% of pts. had an improvement in QOL by 30% or more
(over the 10 years), 15% of pts. saw no change, orsuffered a
decrease, in QOL, 73% of pts. had pain levels decrease by
30% or more, and 14% of the pts. reported no improvement,
or an increase in pain levels over the 10 years.
Paired sample t tests were conducted for each severity
group between assessment periods. Regarding the mild
group, QOL ratings signiﬁcantly improved after treatment,
t(23) = 11.88, p\0.001, ES (Cohen’s d) = 2.07, and pain
ratings signiﬁcantly decreased, t(23) = 10.15, p\0.001,
ES = 2.55.
In the moderate group, QOL signiﬁcantly increased,
t(66) = 9.95, p\0.001, ES = 1.30, and pain levels sig-
niﬁcantly decreased, t(66) = 13.36, p\0.001, ES = 2.26.
Finally, results for the severe group revealed a statistically
signiﬁcant increase in QOL after treatment, t(37) = 9.51,
p\0.001, ES = 1.50, and a signiﬁcant decrease in pain
levels, t(37) = 10.42, p\0.001, ES = 2.16. Overall, the
results suggest that the treatment was effective in
improving QOL and reducing level of pain for all severity
groups (Table 5).
Overall, the medications that helped the most over the
10 years included: opioids (63%), frequent triptans (31%),
butalbital compounds (17%), and onabotulinumtoxinA
(16%) (Table 6).
The majority of opioid patients were taking long-acting
opioids. Only nine patients had worsening headaches due
to the opioids. Frequent triptan patients were carefully
screened and assessed for triptan-induced headache;
patients who had increasing headaches due to triptans were
withdrawn from those drugs.
Discussion
This study categorized RCM patients according to a unique
refractory rating scale. The pts. were evaluated as of the
year 2000, and again 10 years later. Most (60%) of the pts.
had at least a 30% improvement in QOL, while 73% also
experienced a 30% (or more) improvement in pain levels.
While the severe pts. also improved over 10 years, they
still had signiﬁcantly lower QOL, and higher pain scores
than the mild or moderate patients. In this refractory group,
Table 3 Quality of life: year
2000 versus 2010
Initial degree of refractoriness Initial QOL in 2000
(3–30, 30 = worst)
Final QOL
in 2010
% Improvement
in QOL, 2000–2010
Mild (2–4 on refractory scale)
N = 24: average # = 3.79
13.2 8.6 35%
p\0.001, effect size (ES) = 2.07
Moderate (5–7)
N = 67: average # = 6.04
15.8 10.8 32%
p\0.001, ES = 1.30
Severe (8–10)
N = 38: average # = 9.02
21.6 14.4 33%
p\0.001, ES = 1.50
Table 4 Pain level: year 2000 versus 2010
Initial
degree of
refractoriness
Initial pain
level (2000)
(1–10,
10 = worst)
Final pain
level
(2010)
Change (%)
from 2000
to 2010
Mild (2–4)
N = 24
7.8 4.3 -45%
p\0.001, effect
size (ES) = 2.55
Moderate (5–7)
N = 67
7.7 4.5 -42%
p\0.001, ES = 1.30
Severe (8–10)
N = 38
8.6 5.5 -36%
p\0.001, ES = 2.16
Table 5 Overall results (across all groups) N = 129
Initial QOL (2000) = 17 (3–30
scale, 30 = worst)
Final QOL (2010) = 11.4
(33% improvement)
Initial pain level (2000) = 7.96
(1–10 scale, 10 = worst)
Final pain level (2010) = 4.76
(40% improvement)
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used medications.
The refractory rating scale presented here is an initial
attempt to classify RCM pts. according to severity. A
refractory scale may be beneﬁcial for both clinical and
study purposes. Patients with mild RCM will generally be
easier to treat than those with severe RCM. Therapeutic
studies on those with RCM may be less likely to succeed if
the patients have severe RCM versus milder RCM. The
individual components of the scale reﬂect various elements
of refractoriness, including comorbidities. This author
awarded more weight to ‘‘refractory to preventives’’ (2
points) or ‘‘refractory to abortives’’ (2 points) than to the
other components (1 point each), primarily because
refractory to preventives or abortives are central hallmarks
of RCM. In virtually all of the published RCM classiﬁca-
tion papers, refractory to preventives and refractory to
abortives are the main criteria for labeling a patient as
having refractory headache [2, 3]. Therefore, each of those
is more heavily weighted than the other components. One
could easily argue that certain components of our proposed
scale warrant 2 points instead of 1. Heavier weighting
could be given to the number of years of chronic migraine,
the number of days per month, and for medication overuse
headache (MOH). Future studies may address this.
Because the plasticity of the brain may be an important
factor in refractoriness, it is important to include the length
of time of headache (selected for this study at[10 years).
The average number of headache days per month is
important, with 25? days probably being more refractory
than 15–24. Those with every day (deﬁned as 30 days per
month) headache are signiﬁcantly more refractory than
those with 15–25 days per month, and this group may
deserve 2 points (vs. the current one) in our scale. This is
particularly true for those with 24/7, 365 days per year of
RCM and should be considered in future papers.
Associated medical comorbidities often occurring in
those with chronic migraine were included. These condi-
tions may complicate treatment, and add to refractoriness.
For this study, we included the following: IBS,
ﬁbromyalgia, TMD, chronic pelvic pain, painful bladder
syndrome, and chronic fatigue.
Psychiatric comorbidities, commonly seen in RCM
patients,certainlycomplicatetreatment.Signiﬁcantabusein
childhood may predispose one to RCM. Important comor-
bidities include anxiety, depression, the bipolar spectrum,
personality disorders, somatization, and post-traumatic
stress disorder [8, 9]. For this study, severe DSM-IV Axis I
(affective disorders) or any Axis II (personality disorders)
was considered important in refractoriness [7].
Disability should be a part of a refractory scale. Those
who function at a low level, at work or at home, often are
more resistant to treatment. Patients exhibit a wide range of
coping and resilience. Resilience is a combination of nature
and nurture; one can almost predict resilience based upon
the shape of the serotonin transporter gene. This author
believes that disability, or a chronically low level of
functioning, renders it less likely that the RCM will
improve. The level of functioning should factor into a
refractory rating scale.
Medication overuse headache (MOH) is a remarkably
complicated concept; MOH must be distinguished from
medication overuse without resulting headache. It can be
exceedingly difﬁcult to determine who has MOH [5]. For
this study, we used IHS guidelines as to MOH. MOH does
add to refractoriness and resistance to treatment, and
should be included in a refractory scale [5]. Medication
overuse can almost be considered to be part of the syn-
drome of RCM. Only 1 point was given to MOH for the
following reasons: (1) MOH is not a ‘‘hallmark’’ of RCM;
refractory to abortive and preventives is a hallmark, and (2)
MOH may be difﬁcult to distinguish from simple medi-
cation overuse (without resultant headache). However, in
future studies it may be justiﬁed to elevate MOH to 2
points in the refractory scale.
The medications utilized by patients in this study
included: opioids, (usually the long-acting opioids), fre-
quent triptans, butalbital, onabotulinumtoxinA, and stimu-
lants. Virtually all of the patients in this study consumed at
least one daily medication for the entire 10 years.
Table 6 Medications
The following medications were
reported to be beneﬁcial by the
refractory patients. To be listed,
the patient must have found the
medication helpful for their
pain, and to have continued on
the medication for at least
6 months
Opioid Frequent triptans, 4 ? per
week
Butalbital OnabotulinumtoxinA Stimulant Other
Mild 10 11 3 6 4 2
N = 24 42% 46% 13% 25% 17% 8%
Moderate 44 23 11 9 5 6
N = 67 66% 34% 16% 13% 7% 9%
Severe 27 6 8 6 6 4
N = 38 71% 16% 21% 16% 16% 11%
Total 81 40 22 21 15 12
N = 129 63% 31% 17% 16% 12% 9%
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[10, 11]. For RCM patients, it often takes a combination of
medications to achieve even minimal beneﬁts. Many of the
patients in the study took two or more of the listed medi-
cations. For the opioid patients, the vast majority were on
long-acting opioids, where rebound headache was less of a
concern. These patients were carefully screened for ‘‘opi-
oid-induced rebound headache.’’ The opioid patients had
been on these medications prior to the year 2000; this
author almost never initiates opioid treatment in an opioid-
naı ¨ve patient. Nine patients in this study did appear to
worsen over time due to chronic opioid use.
The frequent triptan users were screened and assessed
for ‘‘triptan rebound headache’’. These patients were given
triptan-free ‘‘drug holidays’’ to ascertain if they were in the
rebound state. If they worsened due to triptans, or
improved off of the triptans, the triptan medications were
withdrawn.
The deﬁciencies of this article include:
a) The small number of patients in the mild group may
limit conclusions.
b) The refractory scale is not yet validated. This is an
initial attempt to utilize such a scale and additional
work needs to be done.
c) In the refractory scale (Table 2), the associated medical
conditions(item5)werechosenbecausetheyfrequently
complicate headache treatment, add to dysfunction,
andare, tosomedegree,related pathophysiologicallyto
chronic migraine. Other conditions (diabetes, lupus,
etc.) could reasonably be included as well.
d) The QOL tool included pain, functioning and moods.
This speciﬁc tool for measuring QOL has been
previously utilized, but is not yet well-validated.
e) Patients who stopped treatment at the clinic over the
10 years of the study were not included. Follow-up of
these dropouts would strengthen (or possibly chal-
lenge) our conclusions.
RCM constitutes a small but important subset of
migraine patients. For clinical and study purposes, it is
helpful to categorize RCM patients as to the degree of
refractoriness. After 10 years, the severe patients remained
behind the other groups regarding QOL and level of pain.
However, over the 10 years, all of the groups (mild,
moderate, severe) improved in their QOL and level of pain.
This initial attempt to create a refractory rating scale
should be reﬁned and improved with further study and
research.
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